Baicalin can attenuate the inhibitory effects of mifepristone on Wnt pathway during peri-implantation period in mice

Chen, J.G.; Chen, T.; Ding, Yuanyuan; Han, Li; Zhou, Fei; Chen, W.Z.; Ding, Ming

doi:10.1016/j.jsbmb.2014.11.023

Cited by 13 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, an enlarged alveolar lumen after mifepristone administration is in accordance with a previous report, showing that that loss of mammary gland development associated gene Numb or Numbl/l, leading to an enlarged lumen of alveoli and failure in lactation during pregnancy in mice (Zhang et al, 2016). Mifepristone decreased P 4 or E 2 levels on Pd7, these results were in agreement with previous reports, in which P 4 or E 2 levels declined two days after mifepristone administration in humans or mice (Somell et al, 1990;Chen et al, 2015). However, subsequent increase of E 2 concentrations on Pd10 and Pd16, and of P 4 concentrations on Pd16 after mifepristone administration may be attributed to ovarian response as reported in humans (Somell et al, 1990).…”

Section: Discussionsupporting

confidence: 93%

“…Mifepristone is an effective drug for termination of early pregnancy. Previous reports suggested that mifepristone administration at doses of 1.25-2.50 mg/kg BW on Pd4 had no impact on the reproduction of mice (Huang et al, 2005;Lv et al, 2012;Chen et al, 2015;Yang et al, 2016). However, mifepristone administration at doses of 0.30-2.00 mg/kg BW at approximately Pd8.5 caused 60-100% of abortions in mice (Szekeres-Bartho et al, 1997;Lv et al, 2012).…”

Section: Discussionmentioning

confidence: 93%

“…A previous study in mice reported that the ducts from the nipples and buds were beginning to appear along the smaller ducts on Pd2 or Pd3; on Pd6, alveoli formation was taking place along all the ducts; from Pd7 to Pd12, the growth and budding of mammary gland proceed steadily, and the alveoli developed thickly along ducts until Pd12 (Cole, 1933). Researchers verified that administration of mifepristone at doses of 1.25-2.50 mg/kg BW on Pd4 had little effect on the litter size in mice (Huang et al, 2005;Lv et al, 2012;Chen et al, 2015), whereas when mifepristone was administrated at doses of 0.30-2.00 mg/kg and 0.401-2.50 mg/kg, respectively, on Pd8.5 and on Pd14-19, it induced more than 60% of abortions (Szekeres-Bartho et al, 1997;Lv et al, 2012). Based on the time points of mammary gland development, and the dose range of mifepristone that induce abortion in the studies described above, we administrated mifepristone on Pd4 (0.80, 1.20, 1.60, 2.00, and 2.40 mg/kg BW), Pd8 (0.20, 0.40, 0.60, 0.80, and 1.00 mg/kg BW), and Pd12 (0.10, 0.20, 0.30, 0.40, and 0.50 mg/kg BW) in a pilot study to identify the optimum mifepristone dosage for these time points.…”

Section: Experimental Groups and Treatmentsmentioning

confidence: 99%

“…However, these gene knock-out animals exhibited significant defects in multiple tissues (e.g., ovary, uterus, mammary gland, or lung), or had extremely low survivals rates (Cole et al, 1995;Lydon et al, 1995;Bocchinfuso and Korach, 1997). Since mifepristone treatment during early pregnancy decreased the levels of 17 β-estradiol (E 2 ) and P 4 in mice and humans (Chen et al, 2015;Baev et al, 2017), it was exploited in the present study to disturb the hormone balance, and to establish a murine model for mammary gland dysplasia and postpartum hypogalactia. The milk yields, pup growth, mammary histology, serum hormones, and hormone receptors were assessed to evaluate the model and to explain the mechanisms of milk insufficiency after mifepristone treatment.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Mifepristone Treatment in Pregnant Murine Model Induced Mammary Gland Dysplasia and Postpartum Hypogalactia

Zhu

Jia

Ren

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Mammary gland dysplasia and postpartum hypogalactia often occur in humans and in the livestock breeding industry. However, their underlying mechanisms are not clear yet. Mifepristone, which has a high affinity for progesterone (P 4 ) and glucocorticoid receptors, was exploited here to induce the disorders of mammary gland development and lactation. Four strategies were devised for treating pregnant mice with mifepristone. In the first strategy, mice were administered 1.20 mg mifepristone/kg body weight (BW) on pregnancy day 4 (Pd4). In the second strategy, mifepristone was administered to mice twice, with 1.20 mg/kg BW on Pd4 and 0.40 mg/kg BW on Pd8. In the third strategy, mice were treated with a single dose of 0.40 mg mifepristone/kg BW on Pd8. In the fourth strategy, mice were administered 0.40 mg mifepristone/kg BW on Pd8 and 0.20 mg mifepristone/kg BW on Pd12. The results suggested that mifepristone administration at the dose of 1.20 mg/kg BW on Pd4 caused significant reduction in milk production on lactation day 1 (Ld1), Ld2, and Ld3, as assessed using a weighsuckle-weigh assay. Mammary β-casein expression, milk yields, litter growth rates, gland structure, and serum concentrations of 17-β estrogen (E 2 ), P 4 , prolactin (PRL), growth hormone (GH), corticosterone (CORT) and oxytocin (OT) as well as the receptors of these hormones were determined during pregnancy or lactation after performing the first (Pd4) strategy. The results demonstrated that mifepristone administration during early pregnancy decreased β-casein expression, milk yields and litter growth rates, induced fewer alveoli, enlarged alveolar lumina, and altered the levels of E 2 , P 4 , PRL, GH, CORT, and OT as well as the mRNA expression of these hormonal receptors during pregnancy or early lactation. The present study on pregnant mice treated with mifepristone offers an innovative murine model to study the mechanism underlying mammary gland dysplasia and postpartum hypogalactia.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 93%

Section: Experimental Groups and Treatmentsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mifepristone Treatment in Pregnant Murine Model Induced Mammary Gland Dysplasia and Postpartum Hypogalactia

Zhu

Jia

Ren

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Furthermore, it decreased production of human chorionic gonadotropin (hCG), which in turn results in decreased production of progesterone by the corpus luteum. RU486 has been often used to induce embryo implantation failure or polycystic ovary syndrome in experimental animal models [11,[17][18][19]].…”

Section: Introductionmentioning

confidence: 99%

Administration of Herb Formulation Enhanced Blastocyst Implantation via Iκb Activation in Mouse Endometrium

Jeon

Liu

Cai

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundBaelan Chagsang Bang (BCB), consisting of a mixture of 11 herbs, may be prescribed as a reproductive function supplement to improve ovulation and implantation during the treatment of infertility and recurrent abortion in Oriental Medicine. This study aimed to investigate the effects and mechanisms of action of water-extracted BCB on endometrial receptivity and blastocyst implantation in a mifepristone (RU486)-induced implantation failure model.MethodsIn in vitro, antioxidant potentials of BCB were evaluated using DPPH and superoxide anion radical scavenging assays and DCFH-DA assay. In vivo, C57BL/6 female mice (n = 6 per group) orally received BCB (300 mg/kg/day), a dose similar to that used clinically. BCB was administrated from 7 days before pregnancy until the end of the experiment. They were housed with male mice until pregnancy was confirmed. On day 4 of pregnancy, RU486 (4 mg/kg) was injected subcutaneously to induce implantation failure.ResultsAdministration of the BCB water extract increased the number of newborn pups in BCB-treated mice compared to that of sham-treated mice and improved the number of implantation sites in pregnant mice despite RU486 injection. BCB increased the protein expression level of cyclooxygenase-2 and inducible nitric oxide synthase through IκB activation. Moreover, the expression level of matrix metalloproteinases (MMPs) at the uterus implantation site was up-regulated in the BCB-treated group compared to that of the RU486-treated group. To determine the mechanisms of action of BCB, the anti-oxidative effect of BCB was examined via in vitro assay. The BCB water extract showed strong anti-oxidative effects in the DPPH assay and the superoxide anion free-radical scavenging activity assay.ConclusionOur findings provide evidence that BCB has therapeutic potential against poor endometrial receptivity.

show abstract

Human menstrual blood–derived stem cells promote the repair of impaired endometrial stromal cells by activating the p38 MAPK and AKT signaling pathways

Zhu

Jiang

Pan

et al. 2018

Reproductive Biology

View full text Add to dashboard Cite

Baicalin can attenuate the inhibitory effects of mifepristone on Wnt pathway during peri-implantation period in mice

Cited by 13 publications

References 21 publications

Mifepristone Treatment in Pregnant Murine Model Induced Mammary Gland Dysplasia and Postpartum Hypogalactia

Mifepristone Treatment in Pregnant Murine Model Induced Mammary Gland Dysplasia and Postpartum Hypogalactia

Administration of Herb Formulation Enhanced Blastocyst Implantation via Iκb Activation in Mouse Endometrium

Human menstrual blood–derived stem cells promote the repair of impaired endometrial stromal cells by activating the p38 MAPK and AKT signaling pathways

Contact Info

Product

Resources

About